Butterfly Medical received verification from the FDA approving IDE submission
Butterfly Medical received verification from the FDA approving IDE submission for the Butterfly study. This approval allows Butterfly to begin preparing for our Pivotal trial and plan for initial US procedures in early 2022!
The FDA concluded that sufficient data was provided to support activation of a human clinical study in the US. The decision was based on the total evidence provided, including clinical data from the ongoing “first in man” study in Israel, which verified our early safety and performance outcomes.
On behalf of Butterfly Medical, we are extremely excited to start preparing for our US Pivotal trial and the ability to help many men who suffer from BPH symptoms.
Renaly develops therapeutic neuromodulation ultrasound technology addressing the unmet clinical need of patients suffering from uncontrolled and resistant hypertension.
Supra
SUPRA develops an in-office guided ophthalmic injector.
Its unique design provides a safe and intuitive access to the sub choroidal space to allow new drugs administration.
Serenno Medical
Pioneering Urine-Output (UO) Measuring Device for the ICU
A breakthrough solution for accurate and automatic UO measurement, with lower cost, less workload and improved patient safety.
GerdCare Medical
Electro-Stimulation Devices, for non-invasive treatment of Gastroesophageal Reflux Disease (GERD) a chronic disease.
Developing a novel autonomic integrated diagnostic and therapeutic device used to treat heart failure patients reducing hemodynamic and lung congestions, alleviating dyspnea and improving cardiac loading conditions.
Excita
A new approach to Electric Muscle Stimulation for body sculpting devices – introducing personalized adaptive treatments to the body shaping market.
Cherry Imaging
A full software and hardware solution for image management in aesthetic clinics and using it for marketing and patient retention.
An oral imaging device to screen and detect colon cancer and additional GI diseases using deep learning and big data analysis. The Jubaan device can replace the ineffective fecal blood testing currently used for early detection of Colon cancer
EEG measurement device and algorithms analyzing brain health during major surgical procedures avoiding long term brain damage and POCD (Post Operative Cognitive Deterioration) following deep anesthesia.
Dr. Shimon Eckhouse
Active Chairman
Dr. Eckhouse is the founder, owner and Chairman of Alon Medtech.
An inventor, active entrepreneur and investor in the field of medical devices and medical technology,
Until July 2017 Dr. Eckhouse was the chairman of Syneron Medical Ltd. (Nasdaq ELOS) which he co-founded in 2001, until it was acquired by APAX partners.
Dr. Eckhouse is the chairman and co-founder of Epitomee medical, Rapid Medical, Theranica, RealView. Dr. Eckhouse was a co-founder, chairman and CEO of ColorChip from 2001 to 2003; Was a co-founder of Ventor Medical Technologies and its Chairman until it was acquired by Medtronic in 2009 for $325M
Dr Eckhouse was the founder, chairman and CEO of Lumenis (former ESC) from its inception in 1992 until 1999. He took the company public on Nasdaq in 1996 and raised more than $250M in 3 public offerings, the company reached a valuation of more than $1B returning to its investors more than X120 on their investment in the company.
Dr Eckhouse is the inventor of IPL (Intense Pulsed Light) technology which he brought to market in 1994 in ESC and is the most popular non-invasive energy based technology for a broad range of non-invasive medical aesthetic applications.
Dr Eckhouse holds a BSc in physics from the Technion – Israeli Institute of Technology and a Ph.D. in physics from the University of California at Irvine. He is the author of more than 60 US registered patents and a few hundred international patents and published more than 50 papers in leading refereed journals and conferences.
Assaf Mansour
VP Business Development
Mr. Mansour is a co-founder of Alon Medtech.
Assaf brings extensive experience and expertise in investments due diligence, examines the commercial feasibility, strategic planning, management and business development.
Assaf maintains a long-term commitment to the portfolio companies by working closely with the entrepreneurs and assisting them with business development and keep supporting them after they have become independent and successful companies
Mr. Mansour is serving as an active board member in Sofwave Medical (TASE:SOFW) and several more medical companies.
Prior to founding Alon Medtech, Mr. Mansour worked in high-tech companies for more than 12 years’, with particular expertise in managing international customers. In his last positions he served as account program manager at Comverse and TTI Telecom, where he was responsible for customers across North America and Europe..
Mr. Mansour holds a BSc in Industrial Engineering and an MBA from the Ben-Gurion University of the Negev.
Michael (Miki) Eden
CFO
Mr. Eden has joined Alon Medtech as Chief Financial Officer in 2014. He has over 20 years of experience in VC’s investments and management of high growth technology companies.
Miki has vast experience in M&A and IPO transactions, fund raising, due diligence processes, post-acquisition integration and active management and control over global subsidiaries. Prior to joining Alon Medtech, Michael served as a Financial, Commercial and Operational executive in leading high-growth technology companies such as: Convergin, a provider of service broker platforms to mobile operators, acquired by Oracle; Hobart (Prof Shlomo Ben Haim’s investment group) specializing in active management of its health-care portfolio companies from seed stage through acquisition and IPOs; and Aura Investment a publicly traded investment company focused on early stage investments and active management of technology companies.
Michael has a B.A in accounting and business administration and a Master of Law (LL.M) from Bar Ilan University and is also an Israeli certified public accountant.
Haya works closely with the Alon Medtech Chairman, CEO and management team on business intelligence and Marketing strategy, managing all marketing activities of Alon.
Prior to Alon Medtech, Haya was Marketing Manager leading strategy, budget and execution at a prominent IT integration company; Account manager at a leading PR firm; and Legal intern at Herzog Fox & Neeman – Capital Markets and Securities Dep, worked with public companies in all Corporate and Securities Law matters, engaged in public and private offerings of securities, worked on M&A transactions.
Haya holds an LLB degree form Kiryat Ono Academic College.
Dr. Ruthie Amir
Chief Medical Officer
Dr. Ruthie Amir joined Alon Medtech Ventures as the chief medical officer in 2018.
Prior to joining Alon Medtech Dr. Amir served as the director of clinical research and the head of the regulatory department of Syneron Candela from 2008 to 2017.
Dr. Ruthie Amir graduated from Ben Gurion University Medical School in 1989. From 1996-2000, she completed her post-doctoral fellowship in the Department of Human Genetic, at Baylor College of Medicine, Houston, USA where she worked on the genetic basis of Rett Syndrome. Between 2000-2003 she completed a post-doctoral fellowship in the Department of Cell Biology, Faculty of Medicine, Technion.
Dr. Judith Zilberstein
CEO and CTO
Dr Zilberstein is responsible for managing Alon Medtech, including choosing projects, advancing them into companies and guiding their scientific activity.
Dr Zilberstein leads the marketing strategy together with the companies and forges scientific and commercial ties with external groups. She serves as a board member in the portfolio companies of Alon MedTech.
Dr Zilberstein has more than 20 years’ experience in the medical device industry; Vast experience in investments in the Healthcare and nanotech fields.
She served as GM of Maayan Ventures, an early stage investment fund; an active director/chairperson of numerous early stage companies; CTO & BDD of several entrepreneurial medical oriented companies and technological incubators. Dr Zilberstein is the inventor of a several innovations, in the field of optical sensors and cancer therapy.
Dr Zilberstein holds a BSc in chemistry. MSc in chemical physics and PhD in life science, from the Weizmann Institute of Science, She has published numerous scientific articles.
Filterlex
Next-generation embolic protection device for transcatheter aortic valve implantation (TAVI)
The Filterlex embolic protection device is a filter covered Nitinol frame and filter pockets. Its unique structure diverts embolic particles in the aortic arch to the capturing part of the device, where they remain and are extracted with the device at the end of the procedure.
Superior Dermal Fillers Using a Novel HA Crosslink
Hallura’s products are based on a radically new HA crosslinking technology, characterized by a low concentration of HA, very low crosslinking rates, and very high molecular weight of the HA chains, with no low molecular weight fragments.
Non-contact Atrial Fibrillation ablation therapy with real-time procedure monitoring
Developing the world’s first stand-alone, non-contact guided ultrasound ablation for pulmonary vein isolation with integrated lesion monitoring capabilities. The company’s solution consists of an over-the-wire catheter with a propriatery ultrasound transducer positioned within the pulmonary vein ostium for rapid, non-contact circumfrential ablation with real-time lesion feedback capabilities.
Innovating Non-Invasive Skin Tightening With USBT™
Developed a unique platform for non-invasive skin treatment: Ultrasound Beam Technology – USBT™, distinctive from any other ultrasound technology on the market. An array of ultrasound transducers generates multiple beams of high frequency, high intensity ultrasound energy that penetrates into the skin with minimal divergence such that the energy doesn’t “spread out” as the beams penetrates into the tissue.
For the past twelve years Dr. Makover has managed venture capital investments in the biotech/ medical devices field (Tzina Bio-Perspective, Proseed VC). Previously she held senior management positions in life sciences companies focusing on drugs, diagnostics and tissue engineering.
Dr Makover holds a joint Ph.D degree in life sciences from Columbia University (USA) and Weizmann Institute of Science, (Israel) and did post- doctoral research at the Weizmann Institute in Israel. DR. Makover also holds an MBA degree from Bar-Ilan University.
Dr. Makover is serving as a director of the board of six companies including public traded ones.
Prof. Asher Barzilai
Advisory Board
Prof Asher Barzilai was a director at the Edmond and Lily Safra Children’s Hospital at the Chaim Sheba Medical Center at Tel HaShomer, between 2011-2019. Prof Barzilai, an expert in infectious diseases, is an associate clinical professor of pediatrics at Tel Aviv University’s Sackler Faculty of Medicine.
Prof Barzilai earned his MD from Tel Aviv University, Israel. He specialized in Pediatrics at Mt. Sinai Hospital in New York City. Prof Barzilai holds an MBA from the executive MBA program run jointly by Northwestern and Tel Aviv Universities.
Prof. Asher Barzilai
Prof Asher Barzilai was a director at the Edmond and Lily Safra Children’s Hospital at the Chaim Sheba Medical Center at Tel HaShomer, between 2011-2019. Prof Barzilai, an expert in infectious diseases, is an associate clinical professor of pediatrics at Tel Aviv University’s Sackler Faculty of Medicine.
Prof Barzilai earned his MD from Tel Aviv University, Israel. He specialized in Pediatrics at Mt. Sinai Hospital in New York City. Prof Barzilai holds an MBA from the executive MBA program run jointly by Northwestern and Tel Aviv Universities.
Butterfly Medical
An innovative, implantable device for the treatment of Benign Prostatic Hyperplasia (BPH)
Developing a new generation device that offers a superior alternative to existing BPH minimally invasive treatments. Unlike current treatments that are surgical in nature and therefore require certain level of recovery and carry a risk of complications, the Butterfly Medical device is non-surgical, can be delivered at the comfort of the physician’s office and offers immediate relief.
Next generation continuous endoscopic suturing for minimally invasive surgical procedures
Developing a novel atraumatic, non-ischemic continuous suturing device. The first surgical “sewing machine” for minimally invasive surgery, combining simplicity, strength and durability. A single action, automatic device that generates continuous laparoscopy / flexible endoscopy sutures based on threaded smart anchors whose unique design avoids ischemia and reduces tension on the tissue.
Michael joined Alon Medtech as Chief Financial Officer in 2014. He has over 20 years of management experience in overall financial & commercial strategy, fund raising and capital allocation, M&A transactions, investor relations, governance and risk management. Michael is a Senior executive with vast experience in investing and managing high-growth technology companies, due diligence processes, post-acquisition integration and active management and control over global subsidiaries. He has extensive knowledge of business, legal and tax aspects relating to investments, management and control of portfolio companies in different fields.
Prior to joining Alon Medtech, Michael served as a Financial, Commercial and Operational executive in leading high-growth technology companies such as: Convergin, a provider of service broker platforms to mobile operators, acquired by Oracle; Hobart (Prof Shlomo Ben Haim’s investment group) specializing in active management of its health-care portfolio companies from startup stage through acquisition and IPOs; and Aura Investment a publicly traded investment company focused on early stage investments and active management of technology companies.
Michael has a B.A in accounting and business administration and a Master of Law (LL.M) from Bar Ilan University and is also an Israeli certified public accountant.
Anat Rosenthal
Director of Finance
Anat is overseeing the portfolio companies financial aspects including accounting, budget and tax. Anat has over 10 years experience in providing professional services across a broad range of finance areas.
Prior to Alon MedTech, Anat held senior finance positions for international cooperations, privately-held companies and Hi-Tech companies and also served as a professional department manager for over 8 years.
Anat is an Israeli certified public accountant and holds a B.A in Business Administration and Accounting and a M.B.A (Tax specialization) from the College of Management.
Etel Ackerman Pohoriles
General Counsel
Handling all legal aspects of Alon Medtech Ventures and its portfolio companies including fundraising, corporate law, labor law, clinical trials, commercial transaction, regulatory review as well as advising board of directors and C level executives on ongoing day-to-day issues.
Etel has over 13 years of legal counseling experience starting from commercial litigation through in-house counseling.
Etel holds LL.B from The Interdisciplinary Center in Herzliya and LL.M from the Tel Aviv Berkeley Executive program.
Judith Gal
Advisory Board
Experienced Chief Executive Officer with a demonstrated history of working in the medical device industry and Pharma industry. Skilled in the Cardio Vascular, Neurosurgery, Spine, Minimal invasive surgeries, Medical Devices, High Tech Home Care businesses. Strong background in strategy and business development in the Medtech and Biotech industry.
Judith currently serves as a board member at a number of startups. She is a partner at HM Medical Solution LTD.
Judith has been until recently Medtronic’s Israel CEO for more than 12 years and an executive management member of Medtronic BCEGI region. Before joining Medtronic, Judith held senior management positions at Teva Ltd
Advisory Board
Dr. Adina Makover
For the past twelve years Dr. Makover has managed venture capital investments in the biotech/ medical devices field (Tzina Bio-Perspective, Proseed VC). Previously she held senior management positions in life sciences companies focusing on drugs, diagnostics and tissue engineering.
Dr Makover holds a joint Ph.D degree in life sciences from Columbia University (USA) and Weizmann Institute of Science, (Israel) and did post- doctoral research at the Weizmann Institute in Israel. DR. Makover also holds an MBA degree from Bar-Ilan University.
Dr. Makover is serving as a director of the board of six companies including public traded ones
ClipTip Medical
Develops novel micro clip applier devices for performing regular and advanced micro-laparoscopy
Our multi-clip devices are characterized by a diameter of less than 3 mm, longer clips; larger opening of the clip arms; better visibility of the clip and a secure closure. These features will render our devices superior over existing clip appliers and will make them an ideal tool for both, regular as well as advanced laparoscopy or endoscopy procedures such as: needlescopic surgery; single port surgery; NOTES; and robotic surgery.
Trisol Medical
A Transcatheter Tricuspid Valve Replacement (TTVR)
The Trisol valve is constructed out of nitinol frame with specially designed sail-like leaflet. Its unique design provides a comprehensive solution to Tricuspid Regurgitation and RV dysfunction.
Experienced Chief Executive Officer with a demonstrated history of working in the medical device industry and Pharma industry. Skilled in the Cardio Vascular, Neurosurgery, Spine, Minimal invasive surgeries, Medical Devices, High Tech Home Care businesses. Strong background in strategy and business development in the Medtech and Biotech industry.
Judith currently serves as a board member at a number of startups. She is a partner at HM Medical Solution LTD.
Judith has been until recently Medtronic’s Israel CEO for more than 12 years and an executive management member of Medtronic BCEGI region. Before joining Medtronic, Judith held senior management positions at Teva Ltd
